Search

A recent study conducted by researchers at Shahid Sadoughi University of Medical Sciences in Iran examined the role of mast cells in lichen planus and oral lichenoid reaction lesions. Mast cells are responsible for the accumulation of inflammatory cells in the connective tissue. The study found that the total number of mast cells and degranulated mast cells were significantly higher in both groups compared to the control group. However, there was no significant difference in the number of mast cells or the ratio of degranulated mast cells between the two groups. The researchers concluded that clinical examinations and attention to etiologic factors are important in differentiating these two types of lesions. [Extracted from the article]

A recent study conducted by the Department of Dermatology in New Hyde Park, New York, aimed to assess the validity of using diagnostic codes to identify cases of lichen planus (LP) and lichen planopilaris (LPP) in a large clinical database. The study found that LP and LPP diagnosis codes applied by any physician can generate accurate case cohorts for LP and LPP, respectively. However, the use of LP codes applied by a dermatologist may be necessary to accurately identify non-oral LP cases. This research has been peer-reviewed and provides valuable insights into the diagnosis of these skin conditions. [Extracted from the article]

A recent study conducted at Jiangyin People's Hospital in China explored the relationship between inflammatory cytokines and oral lichen planus (OLP) using the Mendelian randomization (MR) method. The researchers analyzed large-scale datasets from various sources and used multiple analysis methods to determine the causal associations between inflammatory cytokines and OLP. The study identified several inflammatory cytokines that were significantly or potentially associated with OLP, suggesting that these cytokines may play a role in the development of the condition. Further research is needed to fully understand the pathogenesis of OLP and the implications of these findings. [Extracted from the article]

A recent study conducted by the Department of Dermatology has found a significant association between Metabolic Syndrome and Lichen Planus (LP), a chronic dermatosis affecting the skin and mucous membranes. The study included 75 patients with LP and 82 age and sex-matched controls, and Metabolic Syndrome was diagnosed using specific criteria. The results showed that Metabolic Syndrome was more prevalent in LP patients compared to controls, and it was significantly associated with the morphology, severity, and duration of the disease. The study suggests that patients with LP should be screened for Metabolic Syndrome to prevent complications such as Diabetes Mellitus, Cardiovascular Disease, colorectal cancer, and stroke. [Extracted from the article]

A systematic review of the literature on Oral Lichen Planus (OLP) in children was conducted to summarize the pathophysiological aspects and clinical characteristics of the disease. The review found that OLP is a rare chronic inflammatory disease of the oral mucosa, with a prevalence of about 0.03% in children. The most common clinical pattern of OLP in children is the reticular pattern, and the buccal mucosa is the most frequently involved oral site. It is important to differentiate OLP from other oral white lesions and chronic ulcers, as it can cause oral discomfort. [Extracted from the article]

A study conducted at Wuhan University in China explores the role of MALT1, an intracellular signaling protein, in the T-cell immune dysfunction of oral lichen planus (OLP), a T cell-mediated immune mucosal disease. The researchers found that MALT1 expression was elevated in local OLP T cells and mucosal-associated invariant T (MAIT) cells, while reduced in peripheral OLP T cells, MAIT cells, and follicular helper-like MAIT (MAITfh) cells. Inhibition of the mTOR pathway further enhanced the suppression of T-cell proliferation and the promotion of apoptosis induced by the MALT1 inhibitor MI-2. This research provides insights into the pathogenesis of OLP and potential therapeutic targets. [Extracted from the article]

A recent report from the University of Gothenburg in Sweden discusses new findings on oral lichen planus (OLP), a condition affecting the mouth. The study aimed to investigate whether the levels of certain proteins and calcium in saliva differ between patients with OLP and individuals without oral mucosal diseases. The research found that patients with OLP had lower levels of salivary acidic glycoproteins and a higher prevalence of dry mouth compared to those without oral mucosal disease. These findings contribute to our understanding of OLP and its potential impact on oral health. [Extracted from the article]

A study conducted at Kerman University of Medical Sciences in Iran examined the prevalence of white mucosal lesions in dental patients from 2006 to 2022. The study found that 20.9% of the 2,215 patients had at least one type of white lesion, with idiopathic lichen planus being the most common at 57.5%. The majority of patients with white lesions were female. The buccal mucosa was the most commonly involved site. The study concluded that lichen planus was the most common lesion and that there was a high concordance between clinical and histopathologic diagnoses. [Extracted from the article]

A new study conducted by researchers at Southern Medical University explores the inter-relationships between galectin-3 (Gal-3), the NLR family pyrin domain containing 3 (NLRP3) inflammasome, and oral lichen planus (OLP). The study analyzed oral biopsy specimens from 30 patients with erosive OLP and 30 healthy controls. The results showed that patients with erosive OLP had higher levels of Gal-3 and NLRP3 inflammasome compared to the control group. Additionally, there was a positive correlation between Gal-3 and NLRP3 inflammasome. This research provides preliminary insights into the potential role of Gal-3 and NLRP3 inflammasome in OLP. [Extracted from the article]

A study conducted by the Chinese Academy of Medical Sciences aimed to explore the clinical epidemiological characteristics of oral lichen planus (OLP) and identify risk factors for erosive/ulcerative OLP. The study included patients diagnosed with OLP from 11 different hospitals. The average age of patients was 49.2 years, with 61.4% of patients being women. Risk factors for erosive/ulcerative OLP included age, longer duration of the disease, dental calculus, hypertension, diabetes, heart disease, and regions of habitation. The study found that the clinical characteristics of OLP in the Chinese population were consistent with existing reports in developed countries. [Extracted from the article]

A recent study conducted by the Autoimmune Bullous Diseases Research Center focused on mycosis fungoides, a type of cutaneous lymphoma. The researchers reported a case of lichenoid mycosis fungoides, which presented with lichen planus-like histopathologic features. The study emphasizes the diagnostic challenges associated with mycosis fungoides and highlights the importance of multiple biopsies and diagnostic methods to avoid misdiagnosis. The findings underscore the need for awareness of the unique histopathologic findings of mycosis fungoides. [Extracted from the article]

A recent study conducted by researchers at Kerman University of Medical Sciences in Iran investigated the relationship between certain genetic polymorphisms and oral lichen planus (OLP), a chronic inflammatory disease that affects a small percentage of the population. The study found a significant association between the A allele of the TNFa-308 G/A gene and the risk of developing OLP. However, the association between the IFN-g + 874A/T genotype and OLP was not strong enough to predict the likelihood of developing the disease. These findings contribute to our understanding of the genetic factors involved in OLP and may have implications for future research and prevention strategies. [Extracted from the article]

A recent pilot clinical trial study conducted by researchers at Urmia University of Medical Science (UMSU) in Iran has found that green tea tablets may be an effective and complementary therapy for patients with oral lichen planus (OLP), a chronic inflammatory and autoimmune disease of the mouth. The study involved 10 patients with erosive and atrophic OLP who took a daily dose of green tea tablets for one month. The results showed a decrease in pain severity, lesion size, and number of lesions after the intervention. However, further research is needed to determine the long-term effectiveness of green tea tablets for OLP. [Extracted from the article]

A recent study conducted at University Hospital in Girona, Spain focused on esophageal lichen planus (ELP), an inflammatory disorder that affects the skin, mucous membranes, and cutaneous appendages. The study presented the case of a 70-year-old woman with a history of erosive lichen planus in various areas of her body, who was eventually diagnosed with esophageal lichen planus. The patient's condition was refractory and progressed to the development of intraepithelial squamous neoplasia. The researchers reviewed the existing literature on this condition. For more information, readers can refer to the journal article published in Frontiers in Medicine. [Extracted from the article]

A recent study from the University of Hong Kong examined the validity of nomograms in predicting the risk of malignant transformation (MT) in patients with oral leukoplakia (OL) and oral lichen planus (OLP). The study found that the nomograms had satisfactory validity in predicting MT among OL patients, but did not outperform binary dysplasia grading in risk stratification. The research suggests that nomograms may be useful in assessing cancer risk in OL, but further research is needed to improve their accuracy. This study was supported by the Hong Kong Research Grants Council. [Extracted from the article]

A recent report from Ewha Womans University College of Medicine in Seoul, South Korea, discusses a case of linear hypertrophic lichen planus (LP) in a pediatric patient. LP is a chronic inflammatory disease of the skin and mucosa, and the hypertrophic type is characterized by thickened, purplish hyperkeratotic plaques and nodules. The 12-year-old girl in this case presented with warty papules and plaques in a zosteriform configuration along one flank. Treatment with oral doxycycline, a topical corticosteroid, and tacrolimus resulted in significant improvement of the skin lesions after 7 weeks. This case highlights the less common but more severe nature of LP in children, and the rarity of the unilateral, linear hypertrophic type. [Extracted from the article]

A study conducted by researchers at Shiraz University of Medical Sciences in Iran examined the expression of BIRC6 in various oral conditions, including oral squamous cell carcinoma (OSCC), epithelial dysplasia (ED), lichen planus with dysplasia (OLPD), hyperkeratosis (HK), and lichen planus (OLP). BIRC6 is a member of the inhibitor of the apoptosis (IAP) family and has been linked to the development of different types of cancer. The study found that OSCC had the highest expression of BIRC6, suggesting its potential role in the tumorigenesis of OSCC. However, its role in the malignant transformation of OLP has yet to be definitively established. [Extracted from the article]

A recent study conducted by researchers at the University of Prishtina "Hasan Prishtina" in Kosovo has found a potential link between oral lichen planus (OLP) and thyroid gland disorders. The study involved 100 participants, with 50 diagnosed with OLP and 50 with other oral mucosa concerns. The results showed a higher prevalence of hypothyroidism in the OLP group compared to the comparison group. The researchers recommend routine screening for thyroid disease in individuals diagnosed with OLP, particularly women. This study provides valuable insights into the association between OLP and thyroid disease. [Extracted from the article]

A report from Consorci Hospital General Universitari de Valencia in Spain discusses research on Pityriasis Lichenoides, a skin condition. The study focuses on three patients with Pityriasis Lichenoides et Varioliformis Acuta (PLEVA) and highlights the correlations between clinical, dermoscopic, and histological features. The researchers suggest that observing dermatoscopic findings, such as specific vessels and globules, can aid in a rapid diagnosis, potentially avoiding the need for invasive techniques. The study concludes that dermoscopy can be a useful diagnostic tool for PLEVA. [Extracted from the article]

Researchers at Shanghai Jiao Tong University School of Medicine conducted a study on oral leukoplakia (OLK) and oral lichen planus (OLP), which are common precancerous lesions of the oral mucosa. The study aimed to evaluate the expression profiles of circular RNAs (circRNAs) in OLK and OLP and explore their potential role in the pathogenesis of these diseases. High throughput sequencing technology was used to detect differentially expressed circRNAs, and the results showed that circHLA-C was the most significantly upregulated circRNA in both OLK and OLP. The study suggests that circHLA-C may be involved in the etiopathogenesis and progression of OLK and OLP. [Extracted from the article]

A recent report from Johannes Gutenberg University of Mainz in Germany discusses the management of different subtypes of lichen planus (LP) in a joint dermatology-oral surgery clinic. LP is a skin condition that can affect the outer skin, nails, and mucosal areas to varying degrees. The pathogenesis of LP is not fully understood, and targeted therapy is currently lacking. The report emphasizes the advantages of an interdisciplinary clinic that can address various aspects of LP management, including tooth status, nutrition, pain, and the risk of malignant transformation. The quality of life for LP patients is significantly impacted due to frequent clinical visits, pain, difficulty eating certain foods, side effects of medication, and concerns about cancer risk. Regular screening for squamous cell carcinoma is recommended for patients with oral LP. [Extracted from the article]

This document provides information about two separate clinical trials for the treatment of Oral Lichen Planus (OLP), a condition characterized by inflammation and lesions in the mouth. The first trial, NCT06158113, is studying the effects of baricitinib on patients with OLP. It aims to determine the efficacy of baricitinib in treating moderate to severe cases of OLP and its impact on patients' quality of life. Participants will be evaluated, given baricitinib to take at home for six months, and assessed for any potential side effects. The second trial is evaluating the effectiveness of a JAK inhibitor called tofacitinib in treating severe cases of OLP. It is not yet recruiting participants and is estimated to be completed in January 2026. The eligibility criteria for participants are outlined, and the study is being conducted by the University of North Carolina in collaboration with Eli Lilly and Company. The data collected from both trials will be shared with researchers and institutions following publication. [Extracted from the article]

A recent report from Tabriz University of Medical Sciences in Iran discusses the findings of a systematic review and meta-analysis on the treatment of oral lichen planus (OLP). The study compared the effects of lycopene, an herbal intervention, with corticosteroids, the current gold standard treatment for OLP. The meta-analysis found no significant difference between the two groups in terms of reducing pain and improving clinical symptoms after treatment. Lycopene was well-tolerated with no specific adverse effects, suggesting it could be used as an alternative to steroids. Further research is needed to explore the potential of lycopene in OLP treatment. [Extracted from the article]

A study conducted at Memorial University of Newfoundland has found that Upadacitinib, a Janus kinase inhibitor, has shown promise in treating erosive lichen planus, a chronic auto-inflammatory disease that can lead to painful ulcerations of the skin and mucosal surfaces. The study reports a successful case of treating erosive lichen planus with Upadacitinib in a 70-year-old woman with treatment-resistant disease. However, the study also highlights the complication of oral squamous cell carcinoma, which was discovered after the erosive lichen planus had healed. The researchers emphasize the importance of monitoring for mucosal squamous cell carcinoma in areas affected by erosive lichen planus. [Extracted from the article]

A recent study conducted by researchers at the University of Kufa focused on pityriasis lichenoides, an uncommon skin disorder. The study aimed to evaluate the clinical and histological features of pityriasis lichenoides among sixteen Iraqi patients in Najaf. The results showed that pityriasis lichenoides mainly affects young adults, with females being more affected by the chronic variant and males being more affected by the acute variant. The study also found that more urban patients with skin phototype III were affected. The findings of the study were consistent with previous literature on the subject. [Extracted from the article]

A recent study conducted at Hospital Morales Meseguer in Murcia, Spain, explored the potential use of saliva as a diagnostic tool for oral potentially malignant disorders (OPMD), such as oral leukoplakia and oral lichen planus. The study analyzed the salivary levels of adenosine deaminase (ADA), ferritin (FRR), and total proteins (TP) in 59 patients with OPMD and 32 healthy controls. The results showed that there were no significant differences in ADA levels between the two groups, but the levels of FRR and TP were significantly higher in the OPMD group. Specifically, patients with oral lichen planus showed significant differences in FRR and TP levels. The study suggests that ferritin and total proteins may serve as potential salivary biomarkers for oral lichen planus, but further research is needed. Additionally, saliva testing is considered a reliable and noninvasive diagnostic tool that could be used for large-scale screening. [Extracted from the article]

A new report from Sichuan University in China discusses the findings of a study on bullous pemphigoid, a rare autoimmune disease. The study focuses on a specific case of lichen planus pemphigoides (LPP) induced by an anti-PD-1 agent, which presented with clinical features in the oral mucosa. The diagnosis was based on histopathology and immunological studies, and topical therapy was chosen as the treatment, resulting in a good therapeutic effect with no significant recurrence observed after a 2-year follow-up. The research emphasizes the importance of accurate and sensitive diagnosis for effective treatment. [Extracted from the article]

A study conducted by researchers at Chulalongkorn University in Bangkok, Thailand, aimed to evaluate the use of direct immunofluorescence (DIF) in diagnosing oral lichen planus (OLP) and differentiating it from oral lichenoid lesions (OLL) and oral epithelial dysplasia (OED). The study analyzed data from 136 patients with clinical presentations of OLP and found that 86% of patients were DIF-positive. However, the researchers concluded that DIF alone is not sufficient evidence for diagnosing OLP, OLL, or OED, and a histopathological examination is necessary. Long-term follow-up is also crucial for managing patients with dysplastic lesions. [Extracted from the article]

Researchers from Baylor University College of Medicine have published a study on perforating lichen nitidus, a rare subtype of lichen nitidus. The study found that this condition typically affects young male patients and presents as lesions in areas prone to mechanical irritation. The researchers also discovered a unique association between perforating lichen nitidus and atopic dermatitis, with the lesions worsening after successful treatment of the dermatitis. This research provides new insights into the pathophysiology of perforating lichen nitidus. [Extracted from the article]

We aimed to analyse the efficacy of metronidazole as a treatment for OLP. Keywords: Chapel Hill; State:North Carolina; United States; North and Central America; Amebicides; Antibiotics; Antiinfectives; Antiprotozoal Agents; Clinical Research; Clinical Trials and Studies; Dermatological Agents; Dermatology; Drugs and Therapies; Health and Medicine; Lichen Planus; Lichenoid Eruptions; Metronidazole Therapy; Mouth Diseases and Conditions; Nitroimidazoles; Oral Lichen Planus; Pharmaceuticals; Skin Diseases and Conditions; Skin and Connective Tissue Diseases and Conditions; Topical Acne Agents EN Chapel Hill State:North Carolina United States North and Central America Amebicides Antibiotics Antiinfectives Antiprotozoal Agents Clinical Research Clinical Trials and Studies Dermatological Agents Dermatology Drugs and Therapies Health and Medicine Lichen Planus Lichenoid Eruptions Metronidazole Therapy Mouth Diseases and Conditions Nitroimidazoles Oral Lichen Planus Pharmaceuticals Skin Diseases and Conditions Skin and Connective Tissue Diseases and Conditions Topical Acne Agents 1094 1094 1 11/06/23 20231106 NES 231106 2023 NOV 6 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Data detailed on Mouth Diseases and Conditions - Oral Lichen Planus have been presented. [Extracted from the article]

Keywords: Chengdu; People's Republic of China; Asia; Antiinfectives; Antimalarial Agents; Antirheumatics; Clinical Research; Clinical Trials and Studies; Dermatology; Drugs and Therapies; Health and Medicine; Hydroxychloroquine Therapy; Lichen Planus; Lichenoid Eruptions; Mouth Diseases and Conditions; Oral Lichen Planus; Pharmaceuticals; Skin Diseases and Conditions; Skin and Connective Tissue Diseases and Conditions EN Chengdu People's Republic of China Asia Antiinfectives Antimalarial Agents Antirheumatics Clinical Research Clinical Trials and Studies Dermatology Drugs and Therapies Health and Medicine Hydroxychloroquine Therapy Lichen Planus Lichenoid Eruptions Mouth Diseases and Conditions Oral Lichen Planus Pharmaceuticals Skin Diseases and Conditions Skin and Connective Tissue Diseases and Conditions 1879 1879 1 11/06/23 20231106 NES 231106 2023 NOV 6 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Researchers detail new data in Mouth Diseases and Conditions - Oral Lichen Planus. Chengdu, People's Republic of China, Asia, Antiinfectives, Antirheumatics, Clinical Research, Clinical Trials and Studies, Dermatology, Drugs and Therapies, Health and Medicine, Hydroxychloroquine Therapy, Lichen Planus, Lichenoid Eruptions, Mouth Diseases and Conditions, Oral Lichen Planus, Pharmaceuticals, Skin Diseases and Conditions, Skin and Connective Tissue Diseases and Conditions, Antimalarial Agents. [Extracted from the article]